The $6 million financing completed by Cingulate Inc. on November 3, 2025, structured as a non-convertible, unsecured promissory note, is intended to bolster the company's working capital and general corporate purposes.1 While this capital infusion does extend Cingulate's cash runway, the company's own projections indicate it is not sufficient to fully fund operations through the Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026, for its lead asset CTx-1301.2
Here's a breakdown of the situation:
- Financing Details: Cingulate received net proceeds of $6 million from a $6.57 million promissory note with a 9% annual interest rate, maturing in 18 months.1
- Cash Position: As of September 30, 2025, Cingulate reported approximately $6.1 million in cash and cash equivalents.2 Adding the $6 million from the financing brings their total available cash to roughly $12.1 million.
- PDUFA Date: The FDA accepted Cingulate's New Drug Application (NDA) for CTx-1301 and set a PDUFA target action date of May 31, 2026.2
- Cash Runway Projection: Cingulate stated that, including the $6 million debt issuance, they anticipate their cash will satisfy capital needs "into the second quarter of 2026" under their current business plan.2 However, to advance commercialization efforts through the May 31, 2026 PDUFA date, the company explicitly noted a need to raise an additional $7 million to $9 million.2
- Cash Burn Rate: The company's net loss for the three months ended September 30, 2025, was $7.3 million, indicating a significant quarterly cash burn.2
In essence, the $6 million financing provides a partial extension of the cash runway, pushing it into the second quarter of 2026. However, it does not fully bridge the gap to the PDUFA decision date, necessitating further capital raises to cover anticipated expenses through that critical period.
